Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates
/in Dendritic Cells, International Publications, Malignant MelanomaFighting fire with fire: the revival of thermotherapy for gliomas
/in Glioblastoma, Hyperthermia, International PublicationsImmunotherapy prospects in the treatment of lung cancer and mesothelioma
/in International Publications, Malignant Pleural Mesothelioma, NSCLC, SCLCPostoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsTwo is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
/in International Publications, Newcastle Disease VirusConcomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
/in Dendritic Cells, International PublicationsDifferent responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
/in International Publications, Newcastle Disease Virus, Pancreatic CancerClinical trials of dendritic cell-based cancer vaccines in hematologic malignancies
/in Acute Leukemia, Dendritic Cells, International Publications, Multiple Myeloma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer